Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of “Moderate Buy” by Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $5.17.

SGMO has been the topic of a number of recent analyst reports. Jefferies Financial Group cut their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, January 27th. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Truist Financial lowered their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Finally, Barclays upped their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $1.23 on Friday. The company has a market cap of $256.64 million, a P/E ratio of -1.64 and a beta of 1.29. The stock has a fifty day moving average price of $1.73 and a 200 day moving average price of $1.34. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same quarter last year, the company earned ($0.34) EPS. As a group, research analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently modified their holdings of SGMO. Renaissance Technologies LLC raised its position in Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after acquiring an additional 1,528,600 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares in the last quarter. XTX Topco Ltd lifted its stake in Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after buying an additional 272,123 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.